Too much and not enough: revisiting maintenance rituximab in indolent lymphomas.
Too much and not enough: revisiting maintenance rituximab in indolent lymphomas. Haematologica. 2022 02 01; 107(2):353-354.
PMID: 34134474
Indolent lymphomas: introduction to a series highlighting progress and ongoing challenges.
Indolent lymphomas: introduction to a series highlighting progress and ongoing challenges. Haematologica. 2022 01 01; 107(1):4-6.
PMID: 34985229
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. Lancet Haematol. 2017 Apr; 4(4):e176-e182.
PMID: 28314699
New drugs for the treatment of non-Hodgkin lymphomas.
New drugs for the treatment of non-Hodgkin lymphomas. Chin Clin Oncol. 2015 Mar; 4(1):14.
PMID: 25841721
The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance).
The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). Leuk Lymphoma. 2013 Jul; 54(7):1405-10.
PMID: 23194022
Maintenance rituximab revisited: is it worth the cost?
Maintenance rituximab revisited: is it worth the cost? Leuk Lymphoma. 2012 Dec; 53(12):2331-2.
PMID: 22680766
Targeting mTOR in mantle cell lymphoma: current and future directions.
Targeting mTOR in mantle cell lymphoma: current and future directions. Best Pract Res Clin Haematol. 2012 Jun; 25(2):175-83.
PMID: 22687453
Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.
Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol. 2010 Nov 01; 28(31):4740-6.
PMID: 20837940
Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691.
Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691. Leuk Lymphoma. 2009 Oct; 50(10):1606-17.
PMID: 19626540
Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant.
Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. Biol Blood Marrow Transplant. 2008 Aug; 14(8):904-12.
PMID: 18640574